Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.
Published on 3 months, 1 week ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate